The goal is to make the epilepsy treatment drug Xcopri (active ingredient cenobamate) the number one in the U.S. epilepsy treatment market unconditionally. We aim to achieve early entry into the ...

SK Biopharm, which developed the epilepsy drug 'cenobamate,' is entering the digital healthcare market through the development of an artificial intelligence (AI) platform that detects and prevents ...

According to study, over 15 million people are living with a brain disorder without getting diagnosed. Here's what a neurologist says about new treaments that help long-term brain health and daily ...

Epilepsy affects one in every 100 people—1 million in Japan and 50 million worldwide. It is the third most common brain disease after stroke and dementia. In Japan, its incidence and prevalence have ...

The Epilepsy Treatment Market focuses on providing therapeutic interventions for individuals with epilepsy, a neurological disorder characterized by recurrent seizures. Treatment options include ...

Epilepsy is a neurological disorder where nerve cell activity in the brain becomes disrupted, causing seizures, unusual behavior, sensations, and sometimes loss of consciousness. It is a treatable ...